A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford researchers from the Khuri-Yakub group have designed an improved, high spatial resolution ultrasonic neuromodulation device that implements chip waveform instead of continuous wave PIRF.
Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.
Stanford inventors have developed a method to create spatially micropatterned vascularized structures that enable in vitro representation of human and animal biology in models such as cells, tissues, organs, and organoids.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Researchers at Stanford have developed a method using expressed genetic barcodes to enable simultaneous lineage tracing and single cell profiling. Intratumor heterogeneity fosters tumor evolution which is a key contributor to therapeutic failure and the lethality of cancer.
Temporally precise, noninvasive control of neural circuitry is a long-sought goal of neuroscientists and biomedical engineers. Stanford University researchers in the laboratory of Dr.
Researchers in the laboratories of Dr. Karl Deisseroth and Dr. Peter Hegemann have engineered mutant ChR2 (Channelrhodopsin-2) proteins with light-sensitivity that is increased by orders of magnitude compared to wild-type ChR2.
Researchers in Prof. Karl Deisseroth's lab have discovered and engineered new microbial opsin proteins and cell trafficking tools to enable selective cell-type specific, light-sensitive switches for neuromodulation.
Researchers in Dr. Karl Deisseroth's laboratory have developed a novel method to rapidly identify neurophysiological measures associated with psychiatric disease and then use those correlates to screen for therapeutics.
Researchers in Prof. Karl Deisseroth's laboratory have developed a portfolio of microbial opsin proteins that can be used for precise and modular photosensitization components that enable optical control of specific cellular processes.
Researchers in Prof. Karl Diesseroth's laboratory have discovered a Dopamine receptor type 2 specific promoter (D2SP) that can be used to transfect, identify and isolate Dopamine R2 (D2R)-expressing cells.
Researchers in Dr. Karl Deisseroth's lab have developed a selective approach to treat anxiety. Anxiety is characterized by several features that are coordinately regulated by diverse neuronal system outputs.